Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is a, open-label, single-arm 8-week investigation of levodopa/carbidopa/entacapone in the treatment of early Parkinson's disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 80
Healthy Volunteers: f
View:
• Male or female and greater from 30 to 80.
• Diagnosis of idiopathic PD according to the MDS PD Diagnostic Criteria (2015).
• Hoehn-Yahr stage of 1.5-3.0 (open stage).
• Not on anti-PD medication or stable on anti-PD medication for at least 30 days.
Locations
Other Locations
China
The Second Affiliated Hospital of Soochow University
RECRUITING
Shanghai
Contact Information
Primary
Chun-feng Liu, MD,PhD
liuchunfeng@suda.edu.cn
+8613606210609
Time Frame
Start Date: 2023-11-15
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 60
Treatments
Experimental: levodopa/carbidopa/entacapone
levodopa/carbidopa/entacapone is a combination drug consisting of levodopa, carbidopa, and entacapone. Each tablet contains a 1:4 ratio of carbidopa to levodopa and 200 mg of entacapone. The optimum daily dosage of levodopa/carbidopa/entacapone must be determined by careful titration in each patient.
Related Therapeutic Areas
Sponsors
Leads: Second Affiliated Hospital of Soochow University